{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:06:40Z","timestamp":1792843600017,"version":"4.5.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>NUT carcinoma (NC) is a rare subtype of squamous cell carcinoma defined by <jats:italic toggle=\"yes\">NUTM1<\/jats:italic> rearrangements encoding NUT fusion oncoproteins (the most frequent fusion partner being <jats:italic toggle=\"yes\">BRD4<\/jats:italic>) that carries a very poor prognosis, with most patients dying in under 1 year. Only rare primary thyroid NCs have been reported. Here, we evaluated a series of 14 cases. The median patient age at diagnosis was 38 years (range: 17 to 72\u00a0y). Eight of 13 cases with slides available for review (62%) showed a morphology typical of NC, whereas 5 (38%) had a non\u2013NC-like morphology, some of which had areas of cribriform or fused follicular architecture resembling a follicular cell\u2013derived thyroid carcinoma. For cases with immunohistochemistry results, 85% (11\/13) were positive for NUT on biopsy or resection, though staining was significantly decreased on resection specimens due to fixation; 55% (6\/11) were positive for PAX8, and 54% (7\/13) for TTF-1. Tumors with a non\u2013NC-like morphology were all positive for PAX8 and TTF-1. The fusion partner was known in 12 cases: 9 (75%) cases had a <jats:italic toggle=\"yes\">NSD3-NUTM1<\/jats:italic> fusion, and 3 (25%) had a <jats:italic toggle=\"yes\">BRD4-NUTM1<\/jats:italic> fusion. For our cohort, the 2-year overall survival (OS) was 69%, and the 5-year OS was 58%. Patients with NC-like tumors had a significantly worse OS compared with that of patients with tumors with a non\u2013NC-like morphology (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.0462). Our study shows that NC of the thyroid can mimic other thyroid primaries, has a high rate of <jats:italic toggle=\"yes\">NSD3<\/jats:italic>-<jats:italic toggle=\"yes\">NUTM1<\/jats:italic> fusions, and an overall more protracted clinical course compared with nonthyroid primary NC.<\/jats:p>","DOI":"10.1097\/pas.0000000000001967","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T12:13:16Z","timestamp":1661861596000},"page":"1706-1715","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":32,"title":["NUTM1-rearranged Carcinoma of the Thyroid"],"prefix":"10.1097","volume":"46","author":[{"given":"Justine A.","family":"Barletta","sequence":"first","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Gilday","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Afkhami","sequence":"additional","affiliation":[{"name":"Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Bell","sequence":"additional","affiliation":[{"name":"Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Bocklage","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Kentucky College of Medicine, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Boisselier","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, ICM, Montpellier Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole G.","family":"Chau","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, BC Cancer"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Cipriani","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Costes-Martineau","sequence":"additional","affiliation":[{"name":"Department of Pathology, CHU Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald A.","family":"Ghossein","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans J.","family":"Hertzler","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan M.","family":"Kramer","sequence":"additional","affiliation":[{"name":"San Francisco Oncology, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sewanti","family":"Limaye","sequence":"additional","affiliation":[{"name":"Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Lopez","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology & Hematology, Northwell Health Cancer Institute, Donald & Barbara Zucker School of Medicine at Hofstra\/Northwell, Lake Success, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony L.","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annikka","family":"Weissferdt","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songlin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, McGovern Medical School, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"French","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"R1-20250608","first-page":"304","article-title":"BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma","volume":"63","author":"French","year":"2003","journal-title":"Cancer Res"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/annonc\/mdw686","article-title":"Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"pkz094","DOI":"10.1093\/jncics\/pkz094","article-title":"An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) midline carcinoma: analysis of 124 patients","volume":"4","author":"Chau","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/pin.12727","article-title":"NUT carcinoma: clinicopathologic features, pathogenesis, and treatment","volume":"68","author":"French","year":"2018","journal-title":"Pathol Int"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"E4184","DOI":"10.1073\/pnas.1702086114","article-title":"Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma","volume":"114","author":"Alekseyenko","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1101\/gad.267583.115","article-title":"The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains","volume":"29","author":"Alekseyenko","year":"2015","journal-title":"Genes Dev"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/onc.2013.126","article-title":"MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma","volume":"33","author":"Grayson","year":"2014","journal-title":"Oncogene"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1038\/emboj.2010.176","article-title":"Oncogenesis by sequestration of CBP\/p300 in transcriptionally inactive hyperacetylated chromatin domains","volume":"29","author":"Reynoird","year":"2010","journal-title":"EMBO J"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/2159-8290.CD-14-0014","article-title":"NSD3-NUT fusion oncoprotein in NUT midline carcinoma: Implications for a novel oncogenic mechanism","volume":"4","author":"French","year":"2014","journal-title":"Cancer Discov"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/sj.onc.1210852","article-title":"BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells","volume":"27","author":"French","year":"2008","journal-title":"Oncogene"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1200\/JCO.2004.02.107","article-title":"Midline carcinoma of children and young adults with NUT rearrangement","volume":"22","author":"French","year":"2004","journal-title":"J Clin Oncol"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/JTO.0000000000000545","article-title":"Primary pulmonary NUT midline carcinoma: clinical, radiographic, and pathologic characterizations","volume":"10","author":"Sholl","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12105-010-0174-6","article-title":"NUT gene rearrangement in a poorly-differentiated carcinoma of the submandibular gland","volume":"4","author":"Ziai","year":"2010","journal-title":"Head Neck Pathol"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/PAS.0b013e3181abe120","article-title":"NUT midline carcinoma of the parotid gland with mesenchymal differentiation","volume":"33","author":"den Bakker","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2350\/09-10-0727-CR.1","article-title":"NUT midline carcinoma in a newborn with multiorgan disseminated tumor and a 2-year-old with a pancreatic\/hepatic primary","volume":"13","author":"Shehata","year":"2010","journal-title":"Pediatr Dev Pathol"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/PAS.0000000000001021","article-title":"NUTM1 gene fusions characterize a subset of undifferentiated soft tissue and visceral tumors","volume":"42","author":"Dickson","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1002\/cncr.30242","article-title":"Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck","volume":"122","author":"Chau","year":"2016","journal-title":"Cancer"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/PAS.0b013e318198d666","article-title":"Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody","volume":"33","author":"Haack","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/gcc.22838","article-title":"Emerging entities in NUTM1-rearranged neoplasms","volume":"59","author":"McEvoy","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41379-019-0206-z","article-title":"NUTM1-rearranged neoplasia: a multi-institution experience yields novel fusion partners and expands the histologic spectrum","volume":"32","author":"Stevens","year":"2019","journal-title":"Mod Pathol"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.3324\/haematol.2018.206961","article-title":"NUTM1 is a recurrent fusion gene partner in b-cell precursor acute lymphoblastic leukemia associated with increased expression of genes on chromosome band 10p12.31-12.2","volume":"104","author":"Hormann","year":"2019","journal-title":"Haematologica"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11684-020-0821-6","article-title":"Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia","volume":"15","author":"Li","year":"2021","journal-title":"Front Med"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1172\/JCI126185","article-title":"Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma","volume":"129","author":"Sekine","year":"2019","journal-title":"J Clin Invest"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"a003194","DOI":"10.1101\/mcs.a003194","article-title":"A recurrent novel MGA-NUTM1 fusion identifies a new subtype of high-grade spindle cell sarcoma","volume":"4","author":"Diolaiti","year":"2018","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12022-021-09700-2","article-title":"Thyroid carcinoma with NSD3::NUTM1 fusion: a case with thyrocyte differentiation and colloid production","volume":"33","author":"Allison","year":"2022","journal-title":"Endocr Pathol"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1089\/ct.2021;33.38-47","article-title":"NUT carcinoma of the thyroid: an unusual case with a complete response to treatment","volume":"33","author":"Kuo","year":"2021","journal-title":"Clin Thyroidol"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"778296","DOI":"10.3389\/fonc.2021.778296","article-title":"Primary thyroid NUT carcinoma with high PD-L1 expression and novel massive IGKV gene fusions: a case report with treatment implications and literature review","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Oncol"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/his.14370","article-title":"Evaluation of grade in a genotyped cohort of sporadic medullary thyroid carcinomas","volume":"79","author":"Najdawi","year":"2021","journal-title":"Histopathology"},{"key":"R30-20250608","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/S0002-9440(10)63049-0","article-title":"BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19)","volume":"159","author":"French","year":"2001","journal-title":"Am J Pathol"},{"key":"R31-20250608","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"e87062","DOI":"10.1172\/jci.insight.87062","article-title":"Institutional implementation of clinical tumor profiling on an unselected cancer population","volume":"1","author":"Sholl","year":"2016","journal-title":"JCI Insight"},{"key":"R33-20250608","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/cam4.1108","article-title":"Comparative molecular profiling of HPV-induced squamous cell carcinomas","volume":"6","author":"Koncar","year":"2017","journal-title":"Cancer Med"},{"key":"R34-20250608","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1212\/NXG.0000000000000117","article-title":"Copy number analysis reveals a novel multiexon deletion of the COLQ gene in congenital myasthenia","volume":"2","author":"Wang","year":"2016","journal-title":"Neurol Genet"},{"key":"R35-20250608","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/jclinpath-2016-204247","article-title":"Novel exon-exon breakpoint in CIC-DUX4 fusion sarcoma identified by anchored multiplex PCR (archer fusionplex sarcoma panel)","volume":"70","author":"Loke","year":"2017","journal-title":"J Clin Pathol"},{"key":"R36-20250608","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin Cancer Res"},{"key":"R37-20250608","doi-asserted-by":"crossref","first-page":"112313","DOI":"10.18632\/oncotarget.22862","article-title":"Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease","volume":"8","author":"Stirnweiss","year":"2017","journal-title":"Oncotarget"},{"key":"R38-20250608","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/hmg\/ddu749","article-title":"Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing","volume":"24","author":"Kunstman","year":"2015","journal-title":"Hum Mol Genet"},{"key":"R39-20250608","doi-asserted-by":"crossref","first-page":"pkz093","DOI":"10.1093\/jncics\/pkz093","article-title":"Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors","volume":"4","author":"Piha-Paul","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"R40-20250608","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41416-020-01180-1","article-title":"A phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma","volume":"124","author":"Shapiro","year":"2021","journal-title":"Br J Cancer"},{"key":"R41-20250608","first-page":"933","article-title":"Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of NUT carcinoma and other cancers: Results of a phase I\/II open-label, dose escalation study","volume":"150","author":"Cousin","year":"2021","journal-title":"Int J Cancer"},{"key":"R42-20250608","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-22-0591","article-title":"Report of the first international symposium on NUT carcinoma","volume":"28","author":"French","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R43-20250608","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-15-1335","article-title":"Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015\/MK-8628","volume":"6","author":"Stathis","year":"2016","journal-title":"Cancer Discov"},{"key":"R44-20250608","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2018.78.2292","article-title":"Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors","volume":"36","author":"Lewin","year":"2018","journal-title":"J Clin Oncol"},{"key":"R45-20250608","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.surg.2006.07.027","article-title":"Patterns of expression of cell cycle\/apoptosis genes along the spectrum of thyroid carcinoma progression","volume":"140","author":"Saltman","year":"2006","journal-title":"Surgery"},{"key":"R46-20250608","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/PAS.0000000000001602","article-title":"Alterations in Ki67 labeling following treatment of poorly differentiated neuroendocrine carcinomas: a potential diagnostic pitfall","volume":"45","author":"Vyas","year":"2021","journal-title":"Am J Surg Pathol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:03:09Z","timestamp":1749416589000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001967"}},"subtitle":["A Distinct Subset of NUT Carcinoma Characterized by Frequent NSD3-NUTM1 Fusions"],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001967","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,29]]}}}